Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.71 |
| ▸ | MAPT | P10636 | 4/20 | 0.71 |
| ▸ | POLB | P06746 | 2/20 | 0.71 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.71 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.71 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.67 |
| ▸ | HTT | P42858 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | GAA | P10253 | 5/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.63 |
| ▸ | CRHBP | P24387 | 1/20 | 0.61 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.61 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.61 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | XBP1 | P17861 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14096326 | 0.86 | ALDH1A1 (0.74) | RAB9AALDH1A1MAPTPOLBTDP1 | |
| SCHEMBL1871517 | 0.85 | RAB9A (0.69) | RAB9AALDH1A1MAPTPOLBTDP1 | |
| SCHEMBL14096629 | 0.85 | RAB9A (0.69) | RAB9AALDH1A1MAPTPOLBTDP1 | |
| SCHEMBL14096626 | 0.85 | RAB9A (1.00) | RAB9AALDH1A1MAPTPOLBTDP1 | |
| SCHEMBL257816 | 0.84 | EPHX2 (0.76) | RAB9AALDH1A1MAPTPOLBSMN1; SMN2 | |
| SCHEMBL10243034 | 0.81 | ALDH1A1 (0.62) | RAB9AALDH1A1MAPTPOLBTDP1 | |
| SCHEMBL18606697 | 0.81 | CA1 (0.75) | RAB9AALDH1A1MAPTPOLBTDP1 | |
| SCHEMBL14096016 | 0.79 | MAPT (0.74) | RAB9AALDH1A1MAPTTDP1ALOX12 | |
| SCHEMBL5450295 | 0.79 | LMNA (0.76) | RAB9AALDH1A1MAPTPOLBTDP1 | |
| SCHEMBL15840545 | 0.79 | ALDH1A1 (0.69) | RAB9AALDH1A1MAPTPOLBTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9174947-B2 | c-Met modulators and methods of use | Exelixus, Inc. (US) | 2015-11-03 | — | — | US | disclosed |
| US-8178532-B2 | c-Met modulators and method of use | EXELIXIS, INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-8067436-B2 | N-(4-{[7-{[3-(diethylamino)propyl] oxy}-6-(methyloxy) quinazolin-4-yl]oxy}-3- fluorophenyl)-N'-(4- fluorophenyl) cyclopropane-1,1-dicarboxamide; for modulating protein kinase enzymatic activity for modulating cell activities such as proliferation, differentiation, programmed cell death | EXELIXIS, INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-7579473-B2 | N-(4-{[7-{[3-(diethylamino)propyl] oxy}-6-(methyloxy) quinazolin-4-yl]oxy}-3- fluorophenyl)-N'-(4- fluorophenyl) cyclopropane-1,1-dicarboxamide; for modulating protein kinase enzymatic activity for modulating cell activities such as proliferation, differentiation, programmed cell death | EXELIXIS, INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-20090170896-A1 | c-Met modulators and methods of use | EXELIXIS, INC. (US) | 2009-07-02 | — | — | US | disclosed |
| US-20090105299-A1 | c-MET MODULATORS AND METHODS OF USE | EXELIXIS, INC (US) | 2009-04-23 | — | — | US | disclosed |
| US-20080161305-A1 | C-Met Modulators and Methods of Use | EXELIXIS, INC. (US) | 2008-07-03 | — | — | US | disclosed |
| US-20070244116-A1 | c-MET MODULATORS AND METHOD OF USE | EXELIXIS, INC. (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070225307-A1 | C-MET MODULATORS AND METHOD OF USE | EXELIXIS, INC. (US) | 2007-09-27 | — | — | US | disclosed |
| US-20070054928-A1 | c-Met modulators and methods of use | EXELIXIS, INC. (US) | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054928-A1 | c-Met modulators and methods of use | FLT4, FLT1, MET | RAB9A 3070/4885ALDH1A1 2072/4885MAPT 4161/4885 |
| US-20080161305-A1 | C-Met Modulators and Methods of Use | MET, HGFAC, HGF | RAB9A 3398/4885ALDH1A1 2327/4885MAPT 4168/4885 |
| US-20090170896-A1 | c-Met modulators and methods of use | FLT4, MET, FLT1 | RAB9A 3215/4885ALDH1A1 2597/4885MAPT 4108/4885 |
| US-20070225307-A1 | C-MET MODULATORS AND METHOD OF USE | FLT4, MET, FLT1 | RAB9A 3263/4885ALDH1A1 2578/4885MAPT 4118/4885 |
| US-20070244116-A1 | c-MET MODULATORS AND METHOD OF USE | FLT4, MET, FLT1 | RAB9A 3263/4885ALDH1A1 2578/4885MAPT 4118/4885 |
| US-20090105299-A1 | c-MET MODULATORS AND METHODS OF USE | FLT4, MET, FLT1 | RAB9A 3215/4885ALDH1A1 2597/4885MAPT 4108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.